代谢综合征杂志

Prestigious Award for Young Research’s at Metabolic Diseases Meet 2020- Discovering New Exploration in endocrinology and oncology field Metabolic Diseases Conference Committee is glad to announce 2nd International Metabolic Diseases and Liver Cancer Conference during December 07-08, 2020 in Dubai, UAE. Metabolic Diseases Meet 2020 developments are maintaining their momentum. Metabolic Conference program delves into strategic discussions.

Diabetes and Obesity 2020 is together individuals in the scholarly community and society keen on Diabetes and Obesity to share the most recent patterns and imperative issues important to our knowledge.

Digestive Diseases is the branch of medicine Related to the GI tract (stomach and intestines) and the accessory organs of digestion (from the mouth to the anus) focused on the digestive system and its disorders. Some of the conditions treated under this specialty include but are not limited to: Crohn’s disease, Gastroesophageal reflux disease (GERD), inflammatory bowel disease, irritable bowel syndrome, peptic ulcer disease, celiac disease, colon cancer, heartburn, gastric cancer, diverticulitis, and ulcerative colitis. Intestinal problems, such as polyps and cancer, infections, celiac disease, Crohn disease, ulcerative colitis, diverticulitis, malabsorption, short bowel syndrome, and intestinal ischemia. Gastroesophageal reflux disease (GERD), peptic ulcer disease, and hiatal hernia. 

Objective: To compare the effect of Transdermal Testosterone (TT) or Clomiphene Citrate (CC) administration on metabolic control, erectile function and quality of life in patients with T2DM.
Materials and patients: The study population included 40 men with T2DM up to 60 years old, who were on metformin monotherapy at doses up to 2550 mg daily over the last three months. The patients had total testosterone values between 8 and 12 nmol/L and LH levels within the normal range. Other causes of hypogonadism were excluded. The patients were asked to answer the IIEF and the SF-36 surveys. BMI, WC, lipid profile, HbA1c, testosterone, SHBG, LH, FSH, PSA, and albuminuria were monitored at their initial visits, and on the 12th and the 24th weeks. 19 of the patients were treated with TT and 21 with CC.
Results: Both groups corresponded in age, BMI, and HbA1c. Three-month administration of TT resulted in a significant increase of serum T and SHBG levels, and a reduction in BMI, HbA1c, WC, TC, TG, that extended to the 6th month. In the group treated with CC the monitored parameters showed the same dynamics.
In the group treated with TT we found significant improvement in all indicators of IIEF at the 3rd month. At the 6th month of and the overall satisfaction declined. In patients treated with CC it was found a significant improvement in all domains during the follow-up period, but without reaching statistical significance. We found significant improvement in physical (p<0.001) and mental (p<0.01) health and in quality of life (p<0.01) at the 3rd month, that extended until the 6th month.
Conclusions: The on time initiation of treatment, that increases testosterone levels, is essential for the metabolic disorders, erectile dysfunction and quality of life. Trials of a longer duration are required to establish the benefits and risks of that therapy in patients with T2DM and Androgen Deficiency Syndrome.

The “11th World Congress on Endocrinology and Metabolic Disorders” hosted by conference series with the theme, “Exploring Novel Aspects in Endocrinology and Metabolic Disorders” was successfully executed during September 3-4, 2018 in Auckland, New Zealand. The conference offered a unique opportunity to investigators across the globe in order to meet, explore, network and perceive new scientific innovations. The conference received commendable and active participation was received from the Editorial Board Members of OMICS Group Journals as well as from the global scientists, Professors, Academicians, Researcher Scholars and students  from  diverse fields of Diabetes & Endocrinology

The organizing committee members of  Annual Congress on Diabetes, Metabolism, and Obesity have finally revealed the theme for  this year`s Diabetes & Obesity 2020 Conference and it’s going to be Reunite and raise hands against the Metabolic disorders. Conference Series  and the organizing committee of Diabetes & Obesity 2020 acknowledges the efforts and contribution of scholars, researchers, academicians, and scientists in the field of Diabetes & Endocrinology and has decided to introduce various achievement awards for all the participants. Diabetes & Obesity 2020 conference will offer various awards to outstanding researchers, scientists, exceptional graduates or early academicians who have a notable contribution to the field and possess keen interest towards the conference theme. The awards strive in providing a strong professional development opportunity for all researchers at different levels of their careers. Moreover our conferences will provide a much needed time and space for all to interact with colleagues from different parts of the world   and to create long lasting networks and relations. 

Obesity and the related diabetes scourges speak to a genuine concern around the world. Bariatric/metabolic surgery rose in a years ago as a profitable helpful alternative for stoutness and related maladies, including type 2 diabetes mellitus (T2DM). The convoluted system of instruments associated with corpulence and T2DM have not totally characterized yet. There is as yet a level-headed discussion on which would be the primary metabolic deformity prompting metabolic crumbling: insulin protection or hyperinsulinemia? Knowledge into the metabolic impacts of bariatric/metabolic surgery has uncovered that, past weight reduction and nourishment confinement, different instruments can be enacted by the improvements of the gastrointestinal tract, for example, the incretin/hostile to incretin framework, changes in bile corrosive creation and stream, and adjustments of gut miniaturized scale biota; every one of them conceivably associated with the abatement of T2DM. The entire clarification of these systems will prompt a superior comprehension of the pathogenesis of this illness. Our point was to audit a portion of the metabolic instruments engaged in the advancement of T2DM in corpulent patients and additionally in the abatement of this condition in patients submitted to bariatric/metabolic surgery.

Conference Series LLC fosters research excellence and leadership by recognizing the outstanding researchers, exceptional graduates or early academicians who have distinctive enthrallment towards the conference themes. Nominees are judged on past accomplishments, research excellence and outstanding academic achievements. Researchers throughout the world who have been credited with outstanding achievements can make a significant contribution to the advancement of their field, thereby having a positive influence on the society.

Introduction: Retinol Binding Protein 4 (RBP-4), an adipokine, that was identified as key regulator of obesity related insulin resistance and type 2 diabetes, and certain components of metabolic syndrome. Objectives: To study the relation of RBP4 and insulin resistance in patients with visceral obesity and type 2 diabetes mellitus. Patients and Methods: This study was conducted on 74 subjects; classified according to their Body Mass Index (BMI) and Waist Circumference (WC) into three main groups: Group 1: included 27 obese diabetic subjects Group 2: included 28 obese non diabetic subjects. Group 3: included 19 healthy non-obese subjects, serving as control. All patients were assessed for Insulin Resistance (IR) index by HOMA-IR and Assessment of B cell function by HOMA-β, RBP4. Results: RBP4 was significantly higher in group 1 and group 2 compared to group 3(p˃0.05) and was nonsignificant in group 1 compared to group 2. There was non-significant correlation between RBP4 & (anthropometric parameters, lipid profile, FBG, 2HPP, HBA1C, FI, HOMA-IR, HOMA-B) in group 1. RBP4 was significantly negative correlated with (BW, HDL) and significant positive correlated with FI, HOMA-IR in the group 2. In viscerally obese subjects HOMA-B% was lower than diabetes group and control group. Conclusion: RBP4 was correlated to insulin resistance in viscerally obese subjects. Viscerally obese subjects had impaired B cell function they are liable for type 2 diabetes and other metabolic risks